CSL Limited share price hits $100: Where to from here?

Where to next for the share price of healthcare giant CSL Limited (ASX:CSL)?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Blood product and vaccine manufacturer CSL Limited (ASX: CSL) is something of an unusual business. While the stock has recorded a staggering 2,177% return since listing on the S&P/ASX ALL ORDINARIES in the 1990s, it spent most of the last decade hovering around $40 per share.

The advent of online brokerage and the rise of super funds, as well as continued strong performance, share buybacks, and several acquisitions sent the company back above $100 this morning for the third time this year. CSL is now within inches of its all-time high of $102.43 per share and investors must be wondering: Where to next? 

source: Google Finance
source: Google Finance

That question is difficult to answer, although it seems that the company's strong balance sheet, international earnings and penchant for share buybacks will only cause the price to rise over time. Continued high expenditure on Research and Development (R&D) is also likely to result in new products and increased sales in the future, given CSL's growth pipeline.

While investors may be put off by the $100 price tag, this represents a Price to Earnings (P/E) ratio of 25 which is higher than the S&P/ASX 200 average but not exorbitant when it comes attached to a company of the calibre of CSL.

A weak Australian dollar and extensive global diversification are huge draw-cards, and indeed in these respects CSL is hard for Australian investors to match without buying Exchange Traded Funds (ETFs). I wouldn't be surprised to see CSL head higher over the next 12 months as the full benefits of a weaker dollar and the Novartis acquisition are felt.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »